ReviewInternational journal of molecular sciences2021
Molecular Epidemiology of the Main Druggable Genetic Alterations in Non-Small Cell Lung Cancer.
Review in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 110 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
110 citing papers in PubMed, 6 syntheses or guidelines pooled it, 167 citations in OpenAlex.
- Recent advances in diagnostic and therapeutic approaches for pulmonary enteric adenocarcinoma.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Pooled it
- Evaluating Surgical Approaches in Early NSCLC: A Meta-Analysis of Robot-Assisted and Video-Assisted Techniques.Annals of surgical oncology · 2026Pooled it
- Economic evaluations of next-generation sequencing for targeted therapy in non-small cell lung cancer: a systematic review.Frontiers in public health · 2026Pooled it
- Effects of Aidi injection on life quality and incidence of adverse reactions in patients with non-small cell lung cancer compared with traditional chemotherapy: a systematic review and meta-analysis.Frontiers in oncology · 2023Pooled it
- Pooled it
- Durvalumab Plus Tremelimumab in Solid Tumors: A Systematic Review.Advances in therapy · 2021Pooled it
- Low, plasma level‑informed native curcumin concentrations fail to induce cell death in human lung and colorectal cancer cells.Pharmaceutical biology · 2026Article
- Integrated bioinformatics and feature selection-based discovery of ADP-ribosylation-associated biomarkers in non-small cell lung cancer.Oncology letters · 2026Article
- Unveiling BRAF Mutations in Non-small Cell Lung Cancer: State of the Art and Future Perspectives.Lung · 2026Review
- Antibody-Drug Conjugates in Lung Cancer: Promise, Progress, and Persistent Challenges.Current issues in molecular biology · 2026Review
- C-MET tyrosine kinase receptor: mechanisms, clinical applications and future perspectives in cancer therapy.Signal transduction and targeted therapy · 2026Review
- Recent advances in engineered nanozymes for precision lung cancer therapy.Materials today. Bio · 2026Review
- Exploring the Impact of Multiple Gene Mutations on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Response in Asian Nonsmall Cell Lung Cancer Patients.ACS pharmacology & translational science · 2026Review
- Deep learning-based CT radiomics for ALK rearrangement status prediction in lung adenocarcinoma.BMC cancer · 2026Article
- Docetaxel in Non-Small Cell Lung Cancer: A Multi-Centre Real-World Evidence Analysis in the Immunotherapy Era.Current oncology (Toronto, Ont.) · 2026Article
- Real-World Treatment Patterns and Survival in Patients withCurrent oncology (Toronto, Ont.) · 2026Observational
- Perspective of smart nanocapsule swallowable laser-guided for integrated sensing and crispr-mediated cancer gene editing.Cancer gene therapy · 2026Review
- Role of the SOX family in non‑small cell lung cancer: Molecular mechanisms and therapeutic implications (Review).Oncology reports · 2026Review
- Comparative evaluation of machine learning models for predicting PD-L1 high expression in resectable NSCLC: a dual-center study integrating [Frontiers in immunology · 2026Article
- Association between planetary health diet index and lung cancer risk in 106,542 participants: a prospective cohort study.Frontiers in nutrition · 2026Article
50 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer is the leading cause of death for malignancy worldwide. Its molecular profiling has enriched our understanding of cancer initiation and progression and has become fundamental to provide guidance on treatment with targeted therapies. Testing the presence of driver mutations in specific genes in lung tumors has thus radically changed the clinical management and outcomes of the disease. Numerous studies performed with traditional sequencing methods have investigated the occurrence of such mutations in lung cancer, and new insights regarding their frequency and clinical significance are continuously provided with the use of last generation sequencing technologies. In this review, we discuss the molecular epidemiology of the main druggable genetic alterations in non-small cell lung cancer, namely
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.